Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Affiliations

• ¹ Department of Haematology, The Royal Marsden Hospital, London, UK. Martin.Kaiser@icr.ac.uk.
• ² Division of Molecular Pathology, The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, 123 Old Brompton Road, London, SW7 3RP, UK. Martin.Kaiser@icr.ac.uk.
• ³ Department of Hematology, Ankara University, Ankara, Turkey.
• ⁴ Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
• ⁵ Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
• ⁶ Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
• ⁷ Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
• ⁸ Department of Hematology, University Hospital of Salamanca, CIC, IBM CC, Salamanca, Spain.
• ⁹ Department of Haematology, The Royal Marsden Hospital, London, UK.
• ¹⁰ Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia.
• ¹¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
• ¹² Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
• ¹³ Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.